January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

A STAT examination shows how AI-powered biotechs like Absci and Generate Biomedicines routinely aggrandize their AI ...

With a lack of venture capital funding, biotechs are increasingly slashing budget and adapting more virtual principles. Going virtual has been one trend that is gaining popularity in the biotech ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and a plan to develop drugs for brain function and health.

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...

Locating the company in a biotech incubator helps manage these issues and gives the fledgling business a feeling of independence. Financing spin-out biotechs has been a real challenge over recent ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Curie.Bio, the biotech accelerator and investment firm, has raised another $340 million to invest in startups.

Sionna and Odyssey are the fourth and fifth biotech companies to file for IPOs since late December. Over the last three years, however, bursts of IPO activity have typically been followed by longer ...

Merck's (NYSE:MRK) recent acquisition of rights to Chinese biotech LaNova Medicines' cancer ... news for patients and should motivate U.S. biotechs to do the same," they added.